Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerMelinda L. Telli, Andrea L. Richardson, Kirsten M. Timms et al.|Clinical Cancer Research|2016Cited by 1.2k
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trialElizabeth A. Mittendorf, Nadia Harbeck, Anh Nguyen Duc et al.|The Lancet|2020Cited by 1.1k
Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell LinesAshley A. Powell, Stefanie S. Jeffrey, AmirAli Talasaz et al.|PLoS ONE|2012Cited by 528
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and <i>BRCA1</i>/<i>2</i> Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105Melinda L. Telli, James M. Ford, Kristin C. Jensen et al.|Journal of Clinical Oncology|2015Cited by 226
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline UpdateN. Lynn Henry, Angela DeMichele, Mark R. Somerfield et al.|Journal of Clinical Oncology|2022Cited by 127